Cancer

Genmab reports Rina-S ovarian cancer results with a 45.9% response rate

Endpoints News reported that Genmab’s Rina-S had a 45.9% objective response rate in patients with platinum-resistant ovarian cancer.

Reported by 3 outlets Tuesday, October 6, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

The original reports on this story are listed below.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.